Recent clinical studies have further validated these findings: PGRMC1 has been demonstrated as a tumor-promoting factor in glioblastoma, where it modulates tumor progression, immune microenvironment, and therapy response [25, 37]. The gene discussed is PGRMC1; the disease is neoplasm.